DDrare: Database of Drug Development for Rare Diseases

Searched query = "Systemic amyloidosis", "AL amyloidosis", "Immunoglobulin light chain amyloidosis", "Amyloid light-chain amyloidosis", "Familial amyloidosis", "Familial amyloid polyneuropathy", "Senile transthyretin amyloidosis", "Senile TTR amyloidosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 124I-labeled monoclonal antibody Mu 11-1F4; 124I-p5+14 Injection; 1H-Pyrazol; 2',4'-difluoro-4-hydroxy-3-biphenylcarboxylic acid; 2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylat; 2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylate; 26866138; 3-(3-(3,5-DIMETHYL-1H-PYRAZOL-4-YL)PROPOXY)-4-FLUOROBENZOIC ACID; 4'-iodo-4'-deoxydoxorubicin; A01AC02; AG10; AG10 HCl; AL; ALKERAN; ALN-51547; ALN-TTRSC; Acyclovir; Alkeran; Amifostine; Amifostine trihydrate; Amiodarone; Anakinra; Aprotinin; BD; BMDex; BORTEZOMIB; Behavioral: Questionnaires; Behavioral: The M.D. Anderson Symptom Inventory (MDASI); Belantamab mafodotin; Bendamustine; Betamethasone; Bortezomib; Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone; Busulfan; CAEL-101; CC; CC-4047; CC-5013; CHIMERIC FIBRIL-REACTIVE IGG1K MONOCLONAL ANTIBODY 11-1F4; CHX A-DTPA anti-CD66 antibody; CHX-A-DTPA-Anti-CD66; CPHC (carboxy pyrrolidine hexanoyl pyrrolidone carboxylate); CYCLOPHOSPHAMIDE; Carboplatin; Carfilzomib; Carmustine; Chemotherapy; Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4; Cisplatin; Cyclophosphamide; Cyclophosphamide, Bortezomib, dexamethasone; Cyclophosphamide, Bortezomib, dexamethasone plus Daratumumab; Cyclophosphamide, bortezomib, and Dexamethasone (CyBorD); Cyclophosphamide, bortezomib, and dexamethasone (CyBorD); Cyclosporine; D-glucitol; DARATUMUMAB; DEXAMETHASONE; DEXAMETHASONE SODIUM SULFATE; DOXYCYCLINE; DTPA; Daratumumab; Daratumumab co-formulated with recombinant human hyaluronidase (rHuPH20); Darzalex; Deaxamethasone; Decadron; Device: High Cut-off Hemodialysis; Dexametasone; Dexamethason; Dexamethasone; Dexamethasone 4 mg JENAPHARM; Dexamethasone, 40 mg; Dexaton; Dezamizumab; Diflunisal; Diflunisal (dolobid); Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhithmias); Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhythmias) plus EGCG; Dolobid; Donor lymphocytes; Doxorubicin; DoxyHEXAL® tabs 100 mg Tabletten; Doxycycline; EGCG; Elotuzumab; Enbrel; Endoxan; Epigallocatechin; Epigallocatechin-3-gallate (EGCG); Etoposide; FORTECORTIN; Filgrastim; Fludarabine; Fludarabine phosphate; Fortecortin; Foscarnet; Foscarnet sodium; Fx-1006A; GRANULOCYTE COLONY STIMULATING FACTOR; GSK2315698; GSK2398852; GSK3039294; Ganciclovir; Gelatin; Genetic: DNA analysis; Genetic: RNA analysis; Genetic: microarray analysis; Genetic: polymerase chain reaction; Genetic: protein expression analysis; Granulocyte Colony Stimulating Factor; Green Tea; Green Tea Extract; H02AB02; H02AB02 Desametasone; HUMAX-CD38; HuMax-CD38; Human Transthyretin Antisense Oligonucleotide; Humanized IgG1, kappa anti-serum amyloid A and anti-AL amyloid antibody; Hyaluronidase; INOTERSEN; ION-682884; IONIS-TTR Rx; ISIS 420915; Ibrutinib; Imatinib; Imatinib mesylate; Indium; Indium 111-radiolabelled anti-CD66; Indium 111 labelled Anti-CD66; Inoserten; Inotersen; Interferon alfa; Iodo; Isatuximab; Isis 420915/GSK 299872; Ixazomib; JNJ-54767414; JnJ 54767414; KINERET*SC 7SIR 100MG 0,67ML; Kineret; L01AA03; Lenalidomide; Lenalidomide 25mg; Lenalidomide, Dexamethasone and Cyclophosphamide; Lenogastrim; MELFLUFEN; MELPHALAN; Meglumine; Melflufen; Melphalan; Melphalan fulfenamide hydrochloride; Melphalan, thalidomide and dexamethasone; Melphalan-Flufenamide (Melflufen); Miridesap; Mycophenolate; Mycophenolate mofetil; N-methyl D-(2,3,4,5,6-pentahydroxy-hexyl)-ammonium; NEOD001; Neupogen; Null; Oral drops solution; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study; Other: flow cytometry; Other: laboratory biomarker analysis; Other: pharmacological study; PEGYLATED RECOMBINANT HUMAN HYALURONIDASE PH20; PF-06291826-83/Fx-1006A; Phosphate; Pomalidomide; Pomalidomide and Dexamethasone; Procedure: Autologous stem cell transplantation; Procedure: Stem Cell Collection; Procedure: Stem Cell Infusion; Procedure: Stem cell infusion; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: antiviral therapy; Procedure: autologous bone marrow transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: autologous hematopoietic stem cell transplantation (ASCT); Procedure: autologous peripheral blood stem cell transplantation; Procedure: autologous stem cell transplant; Procedure: autologous stem cell transplantation; Procedure: autologous-autologous tandem hematopoietic stem cell transplantation; Procedure: bone marrow ablation with stem cell support; Procedure: infection prophylaxis and management; Procedure: management of therapy complications; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Procedure: quality-of-life assessment; Procedure: stem cell infusion; Propylene Glycol-Free Melphalan Hydrochloride; Propylene glycol; REVLIMID; Radiation: total-body irradiation; Recombinant human hyaluronidase; Recombinant human hyaluronidase PH20; Recombinant interferon alfa; Revlimid; Revusiran; SOM0226; STI-6129; Sargramostim; Siltuximab; Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg); Sodium sulfate; Standard of care therapy; Sulfate; Sunitinib; Sunitinib malate; TOLCAPONE; Tafamidis; Tafamidis Meglumine 20mg Soft Gelatin Capsule (Clinical trial image); Tafamidis Meglumine 20mg Soft Gelatin Capsule (Commerical image); Tafamidis meglumine; Tafamidis meglumine 20 mg soft gelatin capsules; Tasmar; Tea Extract; Thalidomide; Thiotepa; Tolcapone; VELCADE; VELCADE*1FL 3,5MG; Valganciclovir; Velcade; Venetoclax; Vyndaqel; Vyndaqel 20mg soft capsule; Yttrium-90; Yttrium-90 radiolabelled anti-CD66 antibody; Yttrium90 radiolabelled antiCD66; [18F]Florbetaben; [d-glucitol, 1-deoxy-1-(methylamino)-, 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate (1:1)]; [d-glucitol, 1-deoxy-1-(methylamino)-,2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate (1:1)]

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04298372 (ClinicalTrials.gov)	February 20, 2019	3/12/2019	Frontline Lenalidomide for AL Amyloidosis Involving Myocardium	Frontline Lenalidomide for AL Amyloidosis Involving Myocardium: Investigation of Organ Reversing Capacity of Lenalidomide	Amyloidosis Cardiac	Drug: Lenalidomide 25mg	Seoul National University Hospital	NULL	Recruiting	19 Years	99 Years	All	30	Phase 3	Korea, Republic of
2	NCT03252600 (ClinicalTrials.gov)	August 25, 2017	24/7/2017	Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis	A Randomized Phase 2 Trial of Lenalidomide/ Dexamethasone/ Elotuzumab +/- Cyclophosphamide Followed by Lenalidomide/ Dexamethasone/Elotuzumab Maintenance as Second-Line Therapy for Patients With Relapsed AL Amyloidosis	Recurrent Primary Amyloidosis	Drug: Cyclophosphamide;Drug: Dexamethasone;Biological: Elotuzumab;Other: Laboratory Biomarker Analysis;Drug: Lenalidomide;Other: Pharmacological Study	Barbara Ann Karmanos Cancer Institute	National Cancer Institute (NCI);Bristol-Myers Squibb;Multiple Myeloma Research Consortium	Recruiting	18 Years	N/A	All	53	Phase 2	United States
3	NCT01194791 (ClinicalTrials.gov)	October 2010	26/7/2010	Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed	A Multicentric, Phase II Trial of Lenalidomide, Cyclophosphamide and Dexamethasone in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed, Not Candidates for Hematopoietic Stem Cell Transplantation	Primary Systemic Amyloidosis	Drug: Lenalidomide;Drug: Cyclophosphamide;Drug: Dexamethasone	PETHEMA Foundation	NULL	Completed	18 Years	N/A	All	30	Phase 2	Spain
4	NCT00890552 (ClinicalTrials.gov)	April 2009	28/4/2009	A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis	A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis	Leukemia;Amyloidosis	Drug: Lenalidomide;Drug: Melphalan;Drug: Dexamethasone	Stanford University	Celgene Corporation	Completed	18 Years	N/A	All	25	N/A	United States
5	NCT00883623 (ClinicalTrials.gov)	April 2009	15/4/2009	A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis	A Prospective Single Center Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With AL Amyloidosis	Primary Amyloidosis	Drug: Lenalidomide	Heidelberg University	Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH	Completed	18 Years	74 Years	Both	50	Phase 2	Germany
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
6	EUCTR2008-001405-41-DE (EUCTR)	24/10/2008	28/08/2008	A prospective trial of treatment with Lenalidomide-Melphalan-Dexamethason (L-Mel-Dex) in untreated patients with AL amyloidosis (LEOMEX) - LEOMEX	A prospective trial of treatment with Lenalidomide-Melphalan-Dexamethason (L-Mel-Dex) in untreated patients with AL amyloidosis (LEOMEX) - LEOMEX	AL amyloidosis	Trade Name: Revlimid Other descriptive name: Lenalidomide Trade Name: Alkeran Product Code: L01AA03 Other descriptive name: melphalan Trade Name: Fortecortin Other descriptive name: dexamethasone	GMIHO mbH	NULL	Not Recruiting			Female: yes Male: yes			Germany
7	NCT00679367 (ClinicalTrials.gov)	May 2008	14/5/2008	Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis	A Phase II Trial of MRD (Melphalan, Lenalidomide and Dexamethasone) for Patients With AL Amyloidosis	Multiple Myeloma	Drug: dexamethasone;Drug: lenalidomide;Drug: melphalan	Boston Medical Center	NULL	Completed	18 Years	N/A	All	16	Phase 2	United States
8	EUCTR2007-006037-13-IT (EUCTR)	21/02/2008	10/12/2007	An open-label, phase II study of cyclophosphamide, lenalidomide and dexamethasone (CLD) for previously treated patients with AL amyloidosis - ND	An open-label, phase II study of cyclophosphamide, lenalidomide and dexamethasone (CLD) for previously treated patients with AL amyloidosis - ND	amyloidosis AL MedDRA version: 6.1;Level: PT;Classification code 10002022	Trade Name: Revlimid INN or Proposed INN: Cyclophosphamide INN or Proposed INN: Dexamethasone	OSPEDALE POLICLINICO S. MATTEO	NULL	Not Recruiting			Female: yes Male: yes		Phase 2	Italy
9	NCT00981708 (ClinicalTrials.gov)	February 2008	19/9/2009	Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)	A Phase I/II Trial of Lenalidomide Combined With Cyclophosphamide and Intermediate Dose Dexamethasone in Patients With Primary (AL) Systemic Amyloidosis	Amyloidosis	Drug: Lenalidomide , Dexamethasone and Cyclophosphamide	University of Athens	Hellenic Cooperative Oncology Group	Active, not recruiting	18 Years	N/A	Both	37	Phase 1;Phase 2	Greece
10	NCT00607581 (ClinicalTrials.gov)	February 2008	22/1/2008	Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis	An Open-label, Phase II Study of Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis	Amyloidosis	Drug: cyclophosphamide;Drug: lenalidomide;Drug: dexamethasone	IRCCS Policlinico S. Matteo	Celgene Corporation	Completed	18 Years	N/A	Both	21	Phase 2	Italy
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
11	NCT00564889 (ClinicalTrials.gov)	December 2007	28/11/2007	Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis	A Phase II Trial of Lenalidomide (Revlimid®), Cyclophosphamide and Dexamethasone in Patients With Primary Systemic Amyloidosis	Multiple Myeloma and Plasma Cell Neoplasm	Drug: cyclophosphamide;Drug: dexamethasone;Drug: lenalidomide	Mayo Clinic	National Cancer Institute (NCI)	Completed	18 Years	N/A	All	35	Phase 2	United States
12	EUCTR2006-007082-36-GR (EUCTR)	16/10/2007	18/07/2007	A Phase I/II trial of lenalidomide combined with cyclophosphamide and intermediate dose dexamethasone in patients with primary (AL) systemic amyloidosis - CDR in amyloidosis	A Phase I/II trial of lenalidomide combined with cyclophosphamide and intermediate dose dexamethasone in patients with primary (AL) systemic amyloidosis - CDR in amyloidosis	Primary (AL) amyloidosis in untreated patients or patientsw who have failed prior treatments	Trade Name: REVLIMID Trade Name: Endoxan Trade Name: Dexamethasone Trade Name: REVLIMID INN or Proposed INN: Lenalidomide INN or Proposed INN: Deaxamethasone INN or Proposed INN: cyclophosphamide	Hellenic Oncology Cooperative Group	NULL	Not Recruiting			Female: yes Male: yes	55	Phase 1;Phase 2	Greece
13	NCT00166413 (ClinicalTrials.gov)	April 2005	12/9/2005	Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis	A Phase II Trial of CC-5013 in Patients With Primary Systemic Amyloidosis	Amyloidosis	Drug: CC -5013	Mayo Clinic	NULL	Completed	18 Years	N/A	Both	38	Phase 2	United States
14	NCT00091260 (ClinicalTrials.gov)	January 2004	7/9/2004	CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis	A Phase II Trial of the Immunomodulatory Drug CC-5013 for Patients With AL Amyloidosis	Multiple Myeloma	Drug: dexamethasone;Drug: lenalidomide	Vaishali Sanchorawala	Celgene Corporation	Completed	18 Years	N/A	All	82	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04298372
(ClinicalTrials.gov)

February 20, 2019

3/12/2019

Frontline Lenalidomide for AL Amyloidosis Involving Myocardium

Frontline Lenalidomide for AL Amyloidosis Involving Myocardium: Investigation of Organ Reversing Capacity of Lenalidomide

Amyloidosis Cardiac

Drug: Lenalidomide 25mg

Seoul National University Hospital

NULL

Recruiting

19 Years

99 Years

All

Phase 3

Korea, Republic of

NCT03252600
(ClinicalTrials.gov)

August 25, 2017

24/7/2017

Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis

A Randomized Phase 2 Trial of Lenalidomide/ Dexamethasone/ Elotuzumab +/- Cyclophosphamide Followed by Lenalidomide/ Dexamethasone/Elotuzumab Maintenance as Second-Line Therapy for Patients With Relapsed AL Amyloidosis

Recurrent Primary Amyloidosis

Drug: Cyclophosphamide;Drug: Dexamethasone;Biological: Elotuzumab;Other: Laboratory Biomarker Analysis;Drug: Lenalidomide;Other: Pharmacological Study

Barbara Ann Karmanos Cancer Institute

National Cancer Institute (NCI);Bristol-Myers Squibb;Multiple Myeloma Research Consortium

Recruiting

18 Years

N/A

All

Phase 2

United States

NCT01194791
(ClinicalTrials.gov)

October 2010

26/7/2010

Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed

A Multicentric, Phase II Trial of Lenalidomide, Cyclophosphamide and Dexamethasone in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed, Not Candidates for Hematopoietic Stem Cell Transplantation

Primary Systemic Amyloidosis

Drug: Lenalidomide;Drug: Cyclophosphamide;Drug: Dexamethasone

PETHEMA Foundation

NULL

Completed

18 Years

N/A

All

Phase 2

Spain

NCT00890552
(ClinicalTrials.gov)

April 2009

28/4/2009

A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis

Leukemia;Amyloidosis

Drug: Lenalidomide;Drug: Melphalan;Drug: Dexamethasone

Stanford University

Celgene Corporation

Completed

18 Years

N/A

All

N/A

United States

NCT00883623
(ClinicalTrials.gov)

April 2009

15/4/2009

A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis

A Prospective Single Center Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With AL Amyloidosis

Primary Amyloidosis

Drug: Lenalidomide

Heidelberg University

Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH

Completed

18 Years

74 Years

Both

Phase 2

Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2008-001405-41-DE
(EUCTR)

24/10/2008

28/08/2008

A prospective trial of treatment with Lenalidomide-Melphalan-Dexamethason (L-Mel-Dex) in untreated patients with AL amyloidosis (LEOMEX) - LEOMEX

AL amyloidosis

Trade Name: Revlimid
Other descriptive name: Lenalidomide
Trade Name: Alkeran
Product Code: L01AA03
Other descriptive name: melphalan
Trade Name: Fortecortin
Other descriptive name: dexamethasone

GMIHO mbH

NULL

Not Recruiting

Female: yes
Male: yes

Germany

NCT00679367
(ClinicalTrials.gov)

May 2008

14/5/2008

Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

A Phase II Trial of MRD (Melphalan, Lenalidomide and Dexamethasone) for Patients With AL Amyloidosis

Multiple Myeloma

Drug: dexamethasone;Drug: lenalidomide;Drug: melphalan

Boston Medical Center

NULL

Completed

18 Years

N/A

All

Phase 2

United States

EUCTR2007-006037-13-IT
(EUCTR)

21/02/2008

10/12/2007

An open-label, phase II study of cyclophosphamide, lenalidomide and dexamethasone (CLD) for previously treated patients with AL amyloidosis - ND

amyloidosis AL
MedDRA version: 6.1;Level: PT;Classification code 10002022

Trade Name: Revlimid
INN or Proposed INN: Cyclophosphamide
INN or Proposed INN: Dexamethasone

OSPEDALE POLICLINICO S. MATTEO

NULL

Not Recruiting

Female: yes
Male: yes

Phase 2

Italy

NCT00981708
(ClinicalTrials.gov)

February 2008

19/9/2009

Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)

A Phase I/II Trial of Lenalidomide Combined With Cyclophosphamide and Intermediate Dose Dexamethasone in Patients With Primary (AL) Systemic Amyloidosis

Amyloidosis

Drug: Lenalidomide , Dexamethasone and Cyclophosphamide

University of Athens

Hellenic Cooperative Oncology Group

Active, not recruiting

18 Years

N/A

Both

Phase 1;Phase 2

Greece

NCT00607581
(ClinicalTrials.gov)

February 2008

22/1/2008

Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis

An Open-label, Phase II Study of Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis

Amyloidosis

Drug: cyclophosphamide;Drug: lenalidomide;Drug: dexamethasone

IRCCS Policlinico S. Matteo

Celgene Corporation

Completed

18 Years

N/A

Both

Phase 2

Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00564889
(ClinicalTrials.gov)

December 2007

28/11/2007

Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

A Phase II Trial of Lenalidomide (Revlimid®), Cyclophosphamide and Dexamethasone in Patients With Primary Systemic Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

Drug: cyclophosphamide;Drug: dexamethasone;Drug: lenalidomide

Mayo Clinic

National Cancer Institute (NCI)

Completed

18 Years

N/A

All

Phase 2

United States

EUCTR2006-007082-36-GR
(EUCTR)

16/10/2007

18/07/2007

A Phase I/II trial of lenalidomide combined with cyclophosphamide and intermediate dose dexamethasone in patients with primary (AL) systemic amyloidosis - CDR in amyloidosis

Primary (AL) amyloidosis in untreated patients or patientsw who have failed prior treatments

Trade Name: REVLIMID
Trade Name: Endoxan
Trade Name: Dexamethasone
Trade Name: REVLIMID
INN or Proposed INN: Lenalidomide
INN or Proposed INN: Deaxamethasone
INN or Proposed INN: cyclophosphamide

Hellenic Oncology Cooperative Group

NULL

Not Recruiting

Female: yes
Male: yes

Phase 1;Phase 2

Greece

NCT00166413
(ClinicalTrials.gov)

April 2005

12/9/2005

Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis

A Phase II Trial of CC-5013 in Patients With Primary Systemic Amyloidosis

Amyloidosis

Drug: CC -5013

Mayo Clinic

NULL

Completed

18 Years

N/A

Both

Phase 2

United States

NCT00091260
(ClinicalTrials.gov)

January 2004

7/9/2004

CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

A Phase II Trial of the Immunomodulatory Drug CC-5013 for Patients With AL Amyloidosis

Multiple Myeloma

Drug: dexamethasone;Drug: lenalidomide

Vaishali Sanchorawala

Celgene Corporation

Completed

18 Years

N/A

All

Phase 2

United States